Hyep Ivan 4

4 · Bicara Therapeutics Inc. · Filed Mar 5, 2026

Form 4

Period: 2026-03-03

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-03$3.79/sh+7,318$27,734→ 152,673 total
Exercise/Conversion
Common Stock
[F1]
2026-03-03$3.79/sh+6,237$23,637→ 158,910 total
Sale
Common Stock
[F1][F2]
2026-03-03$18.22/sh−13,555$246,910→ 145,355 total
Exercise/Conversion
Common Stock
[F1]
2026-03-04$3.79/sh+2,963$11,229→ 148,318 total
Sale
Common Stock
[F1][F3]
2026-03-04$18.25/sh−2,963$54,062→ 145,355 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-03-03−7,318→ 58,144 total
Exercise: $3.79Exp: 2033-04-05→ Common Stock (7,318 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]
2026-03-03−6,237→ 82,747 total
Exercise: $3.79Exp: 2033-08-08→ Common Stock (6,237 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]
2026-03-04−2,963→ 79,784 total
Exercise: $3.79Exp: 2033-08-08→ Common Stock (2,963 underlying)

Footnotes (5)

[F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
[F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
[F4]The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
[F5]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

Signature

/s/ Lara Meisner, Attorney-in-Fact|2026-03-05

Documents

1 file